An Unimpressive Reiki Study

Key Takeaways

• Study compared Reiki, placebo Reiki, mindfulness, waitlist.
• Primary Reiki vs placebo result not statistically significant.
• Blinding of providers was inadequate, risking bias.
• Subjective outcomes limit interpretability of pain reduction.
• Authors overstate findings, calling them preliminary despite flaws.

Summary

Steven Novella critiques a recent U.S. randomized trial that examined Reiki, placebo Reiki (feiki), mindfulness, and a waitlist for chronic knee osteoarthritis. The study found Reiki reduced symptoms compared to waitlist but not versus feiki, rendering the primary outcome statistically non‑significant. Novella highlights methodological weaknesses such as unblinded providers, subjective self‑report measures, and high dropout rates. He argues the authors overstate preliminary findings despite implausible underlying mechanisms.

Pulse Analysis

Interest in biofield therapies such as Reiki has surged alongside a broader market for non‑pharmacological pain solutions. Proponents market Reiki as a "life‑force" modality capable of easing chronic knee osteoarthritis, yet the scientific community remains skeptical because no plausible mechanism exists for energy manipulation. This skepticism frames the interpretation of any clinical data, demanding that studies meet the highest standards of statistical and clinical significance before claims of efficacy are accepted.

The Utah‑Harvard‑Florida State trial attempted a four‑arm, placebo‑controlled design, but critical flaws undermine its credibility. Providers delivering Reiki and feiki were not blinded, allowing subtle cues to influence participant expectations. The primary outcome relied on self‑reported symptom scores, a highly subjective metric that requires flawless blinding to be meaningful. Moreover, a 10% attrition rate and lack of formal blinding checks raise concerns about bias, while post‑hoc trajectory analyses hint at p‑hacking. Consequently, the study’s headline of "significant reduction" is misleading; the direct Reiki versus feiki comparison failed to reach statistical significance.

For healthcare systems and insurers evaluating complementary therapies, this case illustrates the danger of adopting interventions based on flawed evidence. The study’s modest effect sizes and methodological shortcomings suggest that Reiki offers no advantage over placebo, reinforcing the importance of evidence‑based medicine that weighs plausibility alongside statistical outcomes. Policymakers and clinicians should demand rigorously blinded, objective trials before integrating such therapies into standard pain‑management protocols, protecting patients from costly, ineffective treatments.